Cover; Contents; Contributors; Chapter 1. Acyclovir: Mechanism of Antiviral Action and Potentiation by Ri bonucleotide Reductase Inhibitors; I. Introduction; II. Acyclovir Transport; III. Metabolic Activation of Acyclovir; IV. Mechanism of Antiviral Action; V. Potentiation of the Antiviral Action of Acyclovir; VI. Resistance and Hypersensitivity to Acyclovir; VII. Conclusions; References; Chapter 2. Rational Approaches to Osteoporosis Therapy; I. Introduction; II. Age-Related Changes in Bone Mass; III. Mechanisms of Bone Mass Regulation; IV. Osteoporosis; V. Experimental Approaches.
Text of Note
Chapter 4. Blood-Brain Barrier: Transport Studies in Isolated Brain Capillaries and in Cultured Brain Endothelial CellsI. Introduction; II. Establishment and Characterization of an in Vitro Blood-Brain Barrier Model; III. In Vitro Transport Studies; IV. In Vitro Studies on Regulation of Blood-Brain Barrier Transport; V. Summary; References; Chapter 5. Protein Kinase Inhibitors: Probes for the Functions of Protein Phosphorylation; I. Introduction; II. Inhibitors of Protein Serine/Threonine Kinases; III. Inhibitors of Protein Tyrosine Kinases; IV. Concluding Remarks; References.
Text of Note
Chapter 6. Renin InhibitorsI. Introduction; II. Physical and Functional Properties of Renin; III. Biochemical Evaluation and Specificity of Renin Inhibitors; IV. Design and Structure of Renin Inhibitors; V. Pharmacology of Renin Inhibitors; VI. Conclusion; References; Chapter 7. The Capacitative Model for Receptor-Activated Calcium Entry; I. Introduction; II. Epithelial Cells: Models for Studying Receptor-Activated Ca2+ Signaling; III. Mechanisms of Ca2+ Entry; IV. Conclusions; References; Chapter 8. Calcium Channel Antagonists in the Prevention of Neurotoxicity; I. Introduction.
Text of Note
II. Potential Problems in Interpreting the Effectiveness of Calcium Channel Antagonists in Preventing NeurotoxicityIII. Types of Neurotoxicity Attenuated by Calcium Channel Antagonists; IV. The Hypothesis of Calcium-Associated Neuronal Damage; V. Potential Contribution of T, N, L, and P Types of Calcium Channels to Neurotoxicity; VI. Types of Voltage-Dependent Calcium Channel Antagonists; VII. In Vitro Models of Neurotoxicity and Effects of Calcium Channel Antagonists; VIII. In Vivo Animal Models of Ischemia and Effects of Calcium Channel Antagonists.
Text of Note
VI. Nonpharmacological ConsiderationsVII. Conclusions; References; Chapter 3. Molecular Asymmetry and Its Pharmacological Consequences; I. Introduction; II. Pharmacokinetic Consequences of Chirality; III. Chirality and Polymorphic Drug Disposition; IV. Pharmacodynamic Consequences of Chirality; V. Enantiomer-Enantiomer Interactions; VI. Enantioselective Drug-Enantiomer Interactions; VII. Enantiomeric Impurity and Potential Problems; VIII. Enantiomers as Biochemical Probes; IX. Therapeutic and Regulatory Considerations; X. Therapeutic Drug Monitoring; XI. Conclusions; References.